Comparative Pharmacology
Head-to-head clinical analysis: DILACOR XR versus TAZTIA XT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILACOR XR versus TAZTIA XT.
DILACOR XR vs TAZTIA XT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary arteries and peripheral arterioles, and reduction of myocardial contractility and heart rate.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
Oral, 120 mg or 180 mg once daily. For hypertension, initiate at 120 mg once daily; for angina, initiate at 180 mg once daily. Maximum dose: 360 mg once daily.
None Documented
None Documented
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
3-5 hours (immediate-release) for diltiazem; after TAZTIA XT extended-release, effective half-life is approximately 7-9 hours due to prolonged absorption. Clinical context: steady state achieved in 3-5 days.
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Renal (approximately 60% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion), biliary/fecal (approximately 30-35%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker